FDA Advisors Set to Take on TriClip for TR as TRILUMINATE Questions Loom

The executive summary questions the open-label trial, noting that benefit was driven by a softer QoL endpoint.

Related Keywords

El Paso ,Texas ,United States ,Richard Lange ,Edwards Lifesciences ,Circulatory System Devices Panel ,American College Of Cardiology Scientific Sessions ,Drug Administration Circulatory System Devices Panel ,Md Texas Tech University Health Sciences Center ,Drug Administration ,Abbott Medical ,American College ,Cardiology Scientific Sessions ,New England Journal ,Kansas City Cardiomyopathy Questionnaire ,Texas Tech University Health Sciences Center ,